Abstract
The aetiology and pathophysiology of depression have long been associated with inflammation, at least in a proportion of patients. Altered cytokine activity in the periphery and in the brain has brought support to a concept of depression-associated inflammation. However, these immunological changes – and inflammation in particular – in depression have only been recently targeted for treatment. Non-steroidal anti-inflammatory drugs (NSAIDs) have been proposed to be of clinical use in the treatment of depression either as monotherapy or as adjuncts in combination with antidepressants. Specifically, selective cyclooxygenase (COX)-2 and non-selective COX inhibitor NSAIDs as adjuncts or monotherapy have been trialled clinically. A limited body of clinical research has been conducted with mixed results so far. Although meta-analyses appear to support the use of NSAIDs in acute depression, the overall effect is mainly biased by the effects of celecoxib for which the best evidence exists to date. Efficacy data of non-selective COX inhibitor NSAIDs on depressive symptoms is limited and out of six studies, only a retrospective analysis shows positive results for non-selective COX inhibitor. Clinical data on aspirin, an irreversible inhibitor of both COX-1 and COX-2, are mainly experimental and hypothetical at this stage, but may be promising in depressed patients with concomitant inflammatory conditions. The main problematic factor is that current evidence rests on trials in acute depression. Because of the dynamic nature of depression, it is important exploring if NSAIDs and other anti-inflammatory treatments may have a preventive role in early stages of depression and for relapse prevention. The possible impact of anti-inflammatory treatments on immune changes in different phases of depression warrants caution for a wide and preventive use of anti-inflammatory agents in depression-associated inflammation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Musil R, Schwarz MJ, Riedel M et al (2011) Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression—no influence of celecoxib treatment. J Affect Disord 134:217–225
Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71:171–186
Liu S, Wang X, Li Y et al (2014) Necroptosis mediates TNF-induced toxicity of hippocampal neurons. Biomed Res Int 2014:290182
Uher R, Carver S, Power RA et al (2012) Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. Psychol Med 1–9
Rush AJ, Trivedi MH, Wisniewski SR et al (2006) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231–1242
Setiawan E, Wilson AA, Mizrahi R et al (2015) Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 72:268–275
Dowlati Y, Herrmann N, Swardfager W et al (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446–457
Haroon E, Raison CL, Miller AH (2012) Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37:137–162
Kent S, Bluthe RM, Kelley KW et al (1992) Sickness behavior as a new target for drug development. Trends Pharmacol Sci 13:24–28
March J, Silva S, Petrycki S et al (2004) Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 292:807–820
Hannestad J, Dellagioia N, Bloch M (2011) The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36:2452–2459
Kim SJ, Li J (2013) Caspase blockade induces RIP3-mediated programmed necrosis in Toll-like receptor-activated microglia. Cell Death Dis 4, e716
Capuron L, Ravaud A (1999) Prediction of the depressive effects of interferon alfa therapy by the patient’s initial affective state. N Engl J Med 340:1370
Mendlewicz J, Kriwin P, Oswald P et al (2006) Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol 21:227–231
Rush AJ, Trivedi MH, Wisniewski SR et al (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–1917
Pasco JA, Jacka FN, Williams LJ et al (2010) Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother Psychosom 79:323–325
Rosenstein DL, Lerner D, Cai J (1999) More on the depressive effects of interferon alfa. N Engl J Med 341:849–850
Terrando N, Monaco C, Ma D et al (2010) Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci U S A 107:20518–20522
Stellwagen D, Beattie EC, Seo JY et al (2005) Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 25:3219–3228
Mcdonald EM, Mann AH, Thomas HC (1987) Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet 2:1175–1178
Dantzer R, O’connor JC, Freund GG et al (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56
Eyre H, Baune BT (2012) Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology
Holtzheimer PE, Meeks TW, Kelley ME et al (2008) A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int J Geriatr Psychiatry 23:625–631
Miller GE, Cole SW (2012) Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. Biol Psychiatry 72:34–40
Eyre HA, Stuart M, Baune BT (2014) A phase-specific neuroimmune model of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 54:265–274
Lewinsohn PM, Rohde P, Seeley JR et al (2000) Natural course of adolescent major depressive disorder in a community sample: predictors of recurrence in young adults. Am J Psychiatry 157:1584–1591
Muller N (2013) The role of anti-inflammatory treatment in psychiatric disorders. Psychiatr Danub 25:292–298
Shelton RC (2012) Does concomitant use of NSAIDs reduce the effectiveness of antidepressants? Am J Psychiatry 169:1012–1015
Fava GA, Ruini C, Belaise C (2007) The concept of recovery in major depression. Psychol Med 37:307–317
Peschon JJ, Torrance DS, Stocking KL et al (1998) TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160:943–952
Akhondzadeh S, Jafari S, Raisi F et al (2009) Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 26:607–611
Almeida OP, Alfonso H, Jamrozik K et al (2010) Aspirin use, depression, and cognitive impairment in later life: the health in men study. J Am Geriatr Soc 58:990–992
Almeida OP, Flicker L, Yeap BB et al (2012) Aspirin decreases the risk of depression in older men with high plasma homocysteine. Transl Psychiatry 2, e151
Fond G, Hamdani N, Kapczinski F et al (2013) Effectiveness and tolerance of anti-inflammatory drugs’ add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand
Galecki P, Florkowski A, Bienkiewicz M et al (2010) Functional polymorphism of cyclooxygenase-2 gene (G-765C) in depressive patients. Neuropsychobiology 62:116–120
Golan H, Levav T, Mendelsohn A et al (2004) Involvement of tumor necrosis factor alpha in hippocampal development and function. Cereb Cortex 14:97–105
Muller N, Schwarz MJ, Dehning S et al (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11:680–684
Murray CJ, Vos T, Lozano R et al (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197–2223
Na KS, Lee KJ, Lee JS et al (2013) Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 48C:79–85
O’brien SM, Scott LV, Dinan TG (2004) Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 19:397–403
Peng L, Verkhratsky A, Gu L et al (2015) Targeting astrocytes in major depression. Expert Rev Neurother 15:1299–1306
Song C (2002) The effect of thymectomy and IL-1 on memory: implications for the relationship between immunity and depression. Brain Behav Immun 16:557–568
Warner-Schmidt JL, Vanover KE, Chen EY et al (2011) Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A 108:9262–9267
Zhou W, Yuan J (2014) Necroptosis in health and diseases. Semin Cell Dev Biol
Davis A, Gilhooley M, Agius M (2010) Using non-steroidal anti-inflammatory drugs in the treatment of depression. Psychiatr Danub 22(Suppl 1):S49–S52
Maes M, Bosmans E, De Jongh R et al (1997) Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9:853–858
Galecki P, Galecka E, Maes M et al (2012) The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J Affect Disord 138:360–366
Galecki P, Szemraj J, Bienkiewicz M et al (2009) Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 24:277–286
Aid S, Bosetti F (2011) Targeting cyclooxygenases-1 and -2 in neuroinflammation: therapeutic implications. Biochimie 93:46–51
Berk M, Dean O, Drexhage H et al (2013) Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med 11:74
Nery FG, Monkul ES, Hatch JP et al (2008) Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 23:87–94
Aid S, Langenbach R, Bosetti F (2008) Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation 5:17
Choi SH, Aid S, Choi U et al (2010) Cyclooxygenases-1 and -2 differentially modulate leukocyte recruitment into the inflamed brain. Pharmacogenomics J 10:448–457
Miller AH, Maletic V, Raison CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65:732–741
Gallagher PJ, Castro V, Fava M et al (2012) Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry 169:1065–1072
Haapakoski R, Mathieu J, Ebmeier KP et al (2015) Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 49:206–215
Toben C, Baune BT (2015) An act of balance between adaptive and maladaptive immunity in depression: a role for T lymphocytes. J Neuroimmune Pharmacol 10:595–609
Couch Y, Anthony DC, Dolgov O et al (2013) Microglial activation, increased TNF and SERT expression in the prefrontal cortex define stress-altered behaviour in mice susceptible to anhedonia. Brain Behav Immun 29:136–146
Moylan S, Maes M, Wray NR et al (2012) The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry
Trivedi MH, Rush AJ, Wisniewski SR et al (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40
Camara ML, Corrigan F, Jaehne EJ et al (2014) Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge. Neuropsychopharmacology
Baune BT, Wiede F, Braun A et al (2008) Cognitive dysfunction in mice deficient for TNF- and its receptors. Am J Med Genet B Neuropsychiatr Genet 147B:1056–1064
Group AI (2013) Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials 36:555–564
Beattie EC, Stellwagen D, Morishita W et al (2002) Control of synaptic strength by glial TNFalpha. Science 295:2282–2285
Szelenyi J, Vizi ES (2007) The catecholamine cytokine balance: interaction between the brain and the immune system. Ann N Y Acad Sci 1113:311–324
Maes M (2012) Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression. Metab Brain Dis 27:405–413
Pollmacher T, Haack M, Schuld A et al (2002) Low levels of circulating inflammatory cytokines—do they affect human brain functions? Brain Behav Immun 16:525–532
Dunner DL, Rush AJ, Russell JM et al (2006) Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry 67:688–695
Zhu L, Bi W, Lu D et al (2014) Regulation of ubiquitin-specific processing protease 8 suppresses neuroinflammation. Mol Cell Neurosci
Kohler O, Benros ME, Nordentoft M et al (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71:1381–1391
Longhi L, Ortolano F, Zanier ER et al (2008) Effect of traumatic brain injury on cognitive function in mice lacking p55 and p75 tumor necrosis factor receptors. Acta Neurochir Suppl 102:409–413
Eyre H, Air T, Proctor S et al (2015) A critical review of the efficacy of non-steroidal antiinflammatory drugs in depression. Prog Neuro-Psychopharmacol Biol Psychiatry 57:11–16
Mcafoose J, Baune BT (2009) Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 33:355–366
Licinio J (2011) Translational psychiatry: leading the transition from the cesspool of devastation to a place where the grass is really greener. Transl Psychiatry 1, e1
Conradi HJ, Ormel J, De Jonge P (2011) Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med 41:1165–1174
Fields C, Drye L, Vaidya V et al (2011) Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. Am J Geriatr Psychiatry
Eyre HA, Stuart MJ, Baune BT (2014) A phase-specific neuroimmune model of clinical depression. Prog Neuropsychopharmacol Biol Psychiatry 54:265–274
Eyre H, Baune BT (2012) Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology 37:1397–1416
Leonard B, Maes M (2012) Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 36:764–785
Auriel E, Regev K, Korczyn AD (2014) Nonsteroidal anti-inflammatory drugs exposure and the central nervous system. Handb Clin Neurol 119:577–584
Tobinick EL, Gross H (2008) Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J Neuroinflammation 5:2
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Baune, B.T. (2016). Are Non-steroidal Anti-Inflammatory Drugs Clinically Suitable for the Treatment of Symptoms in Depression-Associated Inflammation?. In: Dantzer, R., Capuron, L. (eds) Inflammation-Associated Depression: Evidence, Mechanisms and Implications. Current Topics in Behavioral Neurosciences, vol 31. Springer, Cham. https://doi.org/10.1007/7854_2016_19
Download citation
DOI: https://doi.org/10.1007/7854_2016_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-51151-1
Online ISBN: 978-3-319-51152-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)